In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

General Electric

http://www.ge.com

Latest From General Electric

Novartis Advances Novel Kidney Disease Therapy Iptacopan

Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.

Clinical Trials Commercial

Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Diversified
  • Medical Devices
  • Other Names / Subsidiaries
    • Amersham
    • Clarient Inc.
    • Asymptote Limited
    • GE Healthcare
    • GE Medical Systems LLC
    • Monica Healthcare
    • Novia Strategies
    • Vital Signs.
    • Xcellerex
UsernamePublicRestriction

Register